Roche unveils PhIII data for flu drug
Roche has unveiled late-stage data showing that its experimental antivrial drug baloxavir marboxil hit efficacy and safety targets in patients with flu.
Read More
Tag: CAPSTONE
- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
